In this interview, Dr. Lalani (CA) talks in detail about the concept, endpoints, and what to expect of the phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
